Cooperative Agreement U01CA305075
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $522K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Virginia, USA
Similar Awards
- This federal Project Grant award of $411,583.00 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) will support research at Virginia Polytechnic Institute & State University (Virginia Tech) to develop a computational model and improve understanding of the relationship between perivascular spaces and interstitial fluid flow in the context of glioma tumor invasion. The project will use advanced MRI techniques to generate dynamic...
- This Project Grant award of $163,640 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to develop novel non-viral gene delivery platforms for the treatment of glioblastoma, an aggressive brain cancer. The study aims to investigate the use of brain-penetrating nanoparticles modified to target tumor cells, and to further optimize gene delivery through focused ultrasound treatment. The research is being conducted at the University of Virginia,...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $451,996 to the University of Texas at Arlington (UTA) to develop high-throughput screening platforms for identifying and validating drugs that can target migrating and treatment-resistant glioblastoma (GBM) cancer cells. The overarching goal is to transform GBM, which is currently a fatal disease, into a more localized condition that can be effectively treated through surgery and/or...
- The National Cancer Institute awarded a $679,176 Project Grant to the University of Texas at Dallas (UTD) to develop a novel and minimally invasive method to enhance the delivery of cancer therapies to spinal cord gliomas, test it in a preclinical spinal cord glioma model, and evaluate its application in large animal models. This award is funded through the Cancer Detection and Diagnosis Research program (CFDA 93.394), which supports innovative scientific research to advance cancer screening,...
- The National Cancer Institute (NCI) awarded a $305,031 Project Grant to Round Table Research, Inc. under the Cancer Treatment Research program (CFDA 93.395) to advance extracellular vesicle (EV) therapy for the treatment of glioblastoma (GBM), an aggressive form of brain cancer. The funded project, conducted in collaboration with researchers at the University of North Carolina-Chapel Hill, seeks to develop engineered tumoricidal EVs derived from induced neural stem cells (iNSCs) as a promising...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $414,482 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Virginia Polytechnic Institute & State University (Virginia Tech) on July 24, 2025. The goal of this 2-year project is to enhance the therapeutic efficacy of the Semliki Forest Virus (SFV), a neurotropic oncolytic virus, against glioblastoma, an aggressive form of brain cancer. The project aims to adapt SFV through...
- The University of Michigan received a $136,412 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) to conduct research on defining and interrupting metabolic processes that support glioblastoma, an aggressive form of brain cancer. The goal of the 2-year project is to determine how glioblastoma tumors co-opt brain-derived metabolites like glutamine and lactate to fuel tumor growth and therapy resistance. The research will use in vitro models to...
- The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research federal grant program (CFDA 93.394), awarded a $244,839 project grant to the University of Virginia. The grant aims to investigate the potential of using magnetic resonance imaging-guided focused ultrasound (MRGFUS) to enhance the delivery and persistence of chimeric antigen receptor (CAR) T cell therapy for pediatric medulloblastoma, a common and challenging brain cancer in children. Under a sub-award,...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $276,544 Project Grant to Ioncologi Inc. on September 1, 2025. The grant supports the development of IOI7, an autologous, ex vivo-expanded, immunomodulatory hematopoietic stem cell (HSC) therapy, for the treatment of immune checkpoint inhibitor-resistant glioblastoma. The key objectives are to: (1) optimize HSC expansion using a closed, scalable, and commercially viable production platform; (2) validate HSC...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...